The Bay Area Hepatitis C Cooperative Research Center (Bay Area HCV Center) will use cutting-edge immunologic technologies in the context of well-designed and diverse retrospective case-control and prospective clinical cohorts to study the human immune response to HCV. We wish to ask the question: why is it that some respond well to standard-of-care therapy and some do not? To address this question, the Center will assemble a strong multidisciplinary team comprised of immunologists and clinical investigators at three different sites associated with the University of California at San Francisco (San Francisco General Hospital, UC Medical Center, and the San Francisco Veterans Affairs Medical Center), the California Pacific Medical Center, the Blood Systems Research Institute, and Kaiser Permanente of Northern California. Such diversity in focus and in location requires a strong administrative and organizational structure to successfully promote synergy between the programmatic elements. The Administrative Core will facilitate the overall organizational structure and administrative activities of the Center, interface with NIH NIAID staff, foster cooperation between projects and cores, encourage criticism and advice from its scientists, promote fiscal responsibility, and provide a flexible administrative structure to assure the continued excellence of the Center and its ability to address the Specific Aims. Specifically, the Administrative Core will: (1) provide an organizational and programmatic structure to promote scientific interactions;(2) provide oversight and planning, set priorities, and establish decision making processes;and (3) ensure that the Center meets all criteria of the multi-project Cooperative Agreement (U19) grant mechanism.
The work of this grant requires that there be a multi-site, multi-disciplinary effort. Such an effort requires a coordinating function, of the type that this Administrative Core will provide, so that priorities can be set, decisions can be made, and the efforts of the research team can move forward as effectively and as efficiently as possible. In such a manner, we hope to be able to define parameters of the immune response to HCV that can be used to inform better therapies for this disease in the future.
|Méndez-Lagares, Gema; Lu, Ding; Chen, Connie et al. (2018) Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 200:1124-1132|
|Dai, Ke-Zheng; Ryan, James C; Naper, Christian et al. (2018) Identification of MHC Class Ib Ligands for Stimulatory and Inhibitory Ly49 Receptors and Induction of Potent NK Cell Alloresponses in Rats. J Immunol 200:2847-2859|
|Price, Jennifer C; Murphy, Rosemary C; Shvachko, Valentina A et al. (2014) Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci 59:3043-52|
|Nabekura, Tsukasa; Kanaya, Minoru; Shibuya, Akira et al. (2014) Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity 40:225-34|
|Hartigan-O'Connor, Dennis J; Lin, Din; Ryan, James C et al. (2014) Monocyte activation by interferon ? is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection. J Infect Dis 209:1602-12|
|Manos, M Michele; Ho, Chanda K; Murphy, Rosemary C et al. (2013) Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes. Patient 6:23-34|
|Cozen, Myrna L; Ryan, James C; Shen, Hui et al. (2013) Nonresponse to interferon-? based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One 8:e61568|